Collegium Pharmaceutical, Inc.
COLL
$35.97
$1.173.36%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 23.62% | 26.34% | 22.61% | 17.17% | 11.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23.62% | 26.34% | 22.61% | 17.17% | 11.41% |
| Cost of Revenue | 7.73% | 12.07% | 11.22% | 9.02% | 4.78% |
| Gross Profit | 26.04% | 28.53% | 24.42% | 18.49% | 12.50% |
| SG&A Expenses | 52.08% | 73.79% | 66.00% | 46.50% | 21.42% |
| Depreciation & Amortization | 34.23% | 53.72% | 48.16% | 30.42% | 13.41% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.67% | 53.27% | 47.49% | 32.30% | 14.79% |
| Operating Income | -4.62% | -20.86% | -21.87% | -11.29% | 4.75% |
| Income Before Tax | -6.04% | -36.84% | -62.47% | -49.91% | 30.15% |
| Income Tax Expenses | 1.26% | -43.15% | -59.52% | -42.18% | 6.53% |
| Earnings from Continuing Operations | -9.13% | -34.03% | -63.69% | -52.95% | 43.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.13% | -34.03% | -63.69% | -52.95% | 43.68% |
| EBIT | -4.62% | -20.86% | -21.87% | -11.29% | 4.75% |
| EBITDA | 12.93% | 8.93% | 6.47% | 6.31% | 8.52% |
| EPS Basic | -7.25% | -32.79% | -63.00% | -51.97% | 45.89% |
| Normalized Basic EPS | -12.76% | -40.14% | -40.32% | -17.50% | 17.69% |
| EPS Diluted | -7.27% | -33.62% | -61.44% | -51.56% | 44.37% |
| Normalized Diluted EPS | -11.66% | -38.55% | -38.46% | -15.27% | 12.40% |
| Average Basic Shares Outstanding | -1.76% | -1.60% | -2.19% | -3.33% | -4.36% |
| Average Diluted Shares Outstanding | -6.58% | -7.23% | -7.85% | -8.43% | 0.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |